The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
Open accessAbstract
Background & Aims Uncontrolled studies show sitagliptin, an oral DPP-4 inhibitor, may improve alanine aminotransferase (ALT) and liver histology in nonalcoholic fatty liver disease (NAFLD) patients. We aimed to compare sitagliptin versus placebo's efficacy in reducing liver fat measured by MRI-derived proton density-fat fraction (MRI-PDFF). Methods This randomized, double-blind, allocation-concealed, placebo-controlled trial included 50 NAFLD patients with pre-diabetes or early diabetes randomized to sitagliptin orally 100 mg/day or placebo for 24 weeks. Primary outcome was liver fat change measured by MRI-PDFF in co-localized regions of interest within each of nine liver segments. Additional advanced assessments included MR spectroscopy (MRS) for internal validation of MRI-PDFF's accuracy, and MR elastography (MRE) and FIBROSpect® II to assess liver fibrosis. Results Sitagliptin was not significantly better than placebo in reducing liver fat measured by MRI-PDFF (mean difference between sitagliptin and placebo arms: −1.3%, p=0.4). Compared to baseline, there were no significant differences in end-of-treatment MRI-PDFF for sitagliptin (18.1% to 16.9%, p=0.27) or placebo (16.6% to 14.0%, p=0.07). The groups had no significant differences for changes in ALT, aspartate aminotransferase, low-density lipoprotein, homeostatic model assessment insulin resistance, and MRE-derived liver stiffness. In both groups at baseline and post-treatment, MRI-PDFF and MRS showed robust correlation coefficients ranging from r2=0.96 to r2=0.99 (p<0.0001), demonstrating the findings’ strong internal validity. FIBROSpect® II showed no changes in the sitagliptin group but was significantly increased in the placebo group (p=0.03). Conclusions Sitagliptin was safe but not better than placebo in reducing liver fat in prediabetic or diabetic patients with NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationArmstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Williams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.001 · Cited by 1,775
Loomba, R., & Sanyal, A. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.171 · Cited by 1,641
Self-citationQuantitative assessment of liver fat with magnetic resonance imaging and spectroscopy
Reeder, S. B., Cruite, I., Hamilton, G., & Sirlin, C. B. (2011) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.22580 · Cited by 822
Self-citationImajo, K., Kessoku, T., Honda, Y., Tomeno, W., Ogawa, Y., Mawatari, H., Fujita, K., Yoneda, M., Taguri, M., Hyogo, H., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.11.048 · Cited by 812
Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721
Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP‐1c
Ferré, P., & Foufelle, F. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01275.x · Cited by 704
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625
Noureddin, M., Lam, J., Peterson, M. R., Middleton, M., Hamilton, G., Le, T.-A., Bettencourt, R., Changchien, C., Brenner, D. A., Sirlin, C., et al. (2013) · Hepatology · doi:10.1002/hep.26455 · Cited by 550
Self-citationHarnois, D. (2009) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(09)79298-0 · Cited by 505
Wong, V. W.-S., Chu, W. C.-W., Wong, G. L.-H., Chan, R. S.-M., Chim, A. M.-L., Ong, A., Yeung, D. K.-W., Yiu, K. K.-L., Chu, S. H.-T., Woo, J., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300342 · Cited by 491
Loomba, R., Wolfson, T., Ang, B., Hooker, J., Behling, C., Peterson, M., Valasek, M., Lin, G., Brenner, D., Gamst, A., et al. (2014) · Hepatology · doi:10.1002/hep.27362 · Cited by 489
Self-citationLoomba, R., Abraham, M., Unalp, A., Wilson, L., Lavine, J., Doo, E., & Bass, N. M. (2012) · Hepatology · doi:10.1002/hep.25772 · Cited by 481
Self-citationChen, J., Talwalkar, J. A., Yin, M., Glaser, K. J., Sanderson, S. O., & Ehman, R. L. (2011) · Radiology · doi:10.1148/radiol.11101942 · Cited by 432
Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study
Loomba, R., Schork, N., Chen, C.-H., Bettencourt, R., Bhatt, A., Ang, B., Nguyen, P., Hernandez, C., Richards, L., Salotti, J., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.011 · Cited by 389
Self-citationRatziu, V., Charlotte, F., Bernhardt, C., Giral, P., Halbron, M., LeNaour, G., Hartmann-Heurtier, A., Bruckert, E., & Poynard, T. (2010) · Hepatology · doi:10.1002/hep.23270 · Cited by 366
Permutt, Z., Le, T. ‐., Peterson, M. R., Seki, E., Brenner, D. A., Sirlin, C., & Loomba, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05121.x · Cited by 346
Self-citationLoomba, R., Sirlin, C. B., Ang, B., Bettencourt, R., Jain, R., Salotti, J., Soaft, L., Hooker, J., Kono, Y., Bhatt, A., et al. (2015) · Hepatology · doi:10.1002/hep.27647 · Cited by 344
Self-citationPatel, K., Gordon, S. C., Jacobson, I., Hézode, C., Oh, E., Smith, K. M., Pawlotsky, J.-M., & McHutchison, J. G. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.08.008 · Cited by 330
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis
LOOMBA, R., LUTCHMAN, G., KLEINER, D. E., RICKS, M., FELD, J. J., BORG, B. B., MODI, A., NAGABHYRU, P., SUMNER, A. E., LIANG, T. J., et al. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03869.x · Cited by 299
Self-citationLin, S. C., Heba, E., Wolfson, T., Ang, B., Gamst, A., Han, A., Erdman, J. W., O’Brien, W. D., Andre, M. P., Sirlin, C. B., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.11.027 · Cited by 254
Self-citationLe, T.-A., Chen, J., Changchien, C., Peterson, M. R., Kono, Y., Patton, H., Cohen, B. L., Brenner, D., Sirlin, C., & Loomba, R. (2012) · Hepatology · doi:10.1002/hep.25731 · Cited by 243
Self-citationAdvanced Fibrosis in Nonalcoholic Fatty Liver Disease: Noninvasive Assessment with MR Elastography
Kim, D., Kim, W. R., Talwalkar, J. A., Kim, H. J., & Ehman, R. L. (2013) · Radiology · doi:10.1148/radiol.13121193 · Cited by 231
DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis
Monami, M., Lamanna, C., Desideri, C. M., & Mannucci, E. (2012) · Advances in Therapy · doi:10.1007/s12325-011-0088-z · Cited by 217
Non‐invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE
Doycheva, I., Cui, J., Nguyen, P., Costa, E. A., Hooker, J., Hofflich, H., Bettencourt, R., Brouha, S., Sirlin, C. B., & Loomba, R. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13405 · Cited by 210
Self-citationBazick, J., Donithan, M., Neuschwander-Tetri, B. A., Kleiner, D., Brunt, E. M., Wilson, L., Doo, E., Lavine, J., Tonascia, J., & Loomba, R. (2015) · Diabetes Care · doi:10.2337/dc14-1239 · Cited by 206
Self-citationLoomba, R., Cui, J., Wolfson, T., Haufe, W., Hooker, J., Szeverenyi, N., Ang, B., Bhatt, A., Wang, K., Aryafar, H., et al. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.65 · Cited by 202
Self-citationCui, J., Heba, E., Hernandez, C., Haufe, W., Hooker, J., Andre, M. P., Valasek, M. A., Aryafar, H., Sirlin, C. B., & Loomba, R. (2016) · Hepatology · doi:10.1002/hep.28337 · Cited by 191
Self-citationHerman, G. A., Bergman, A., Liu, F., Stevens, C., Wang, A. Q., Zeng, W., Chen, L., Snyder, K., Hilliard, D., Tanen, M., et al. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006289850 · Cited by 186
Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, and Hepatocellular Carcinoma
Noureddin, M., & Rinella, M. E. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.01.012 · Cited by 181
Cui, J. Y., Ang, B., Haufe, W. M., Hernandez, C., Verna, E. C., Sirlin, C. B., & Loomba, R. S. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13196 · Cited by 162
Self-citationEffect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes
Tremblay, A. J., Lamarche, B., Deacon, C. F., Weisnagel, S. J., & Couture, P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01362.x · Cited by 160
(2012) · Gastroenterology · doi:10.1053/j.gastro.2012.07.001 · Cited by 144
Idılman, R., Mızrak, D., CORAPCIOGLU, D., Bektaş, M., Doğanay, B., Saykı, M., Çoban, Ş., Erden, E., Soykan, İ., Emral, R., et al. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03723.x · Cited by 128
Patel, N. S., Peterson, M. R., Brenner, D. A., Heba, E. R., Sirlin, C. B., & Loomba, R. S. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12237 · Cited by 127
Self-citationEffects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis.
Yilmaz, Y. N., Yönal, O., Deyneli, O., Çelikel, Ç., Kalaycı, C., & Duman, D. (2012) · PubMed · Cited by 122
Arulanandan, A., Ang, B., Bettencourt, R., Hooker, J. C., Behling, C. A., Lin, G., Valasek, M. A., Ix, J. H., Schnabl, B., Sirlin, C. B., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.01.027 · Cited by 105
Self-citationZarrinpar, A., Gupta, S., Maurya, M. R., Subramaniam, S., & Loomba, R. (2016) · Gut · doi:10.1136/gutjnl-2015-309456 · Cited by 88
Self-citationAssessment of FIBROSpect II to Detect Hepatic Fibrosis in Chronic Hepatitis C Patients
Zaman, A., Rosen, H. R., Ingram, K., Corless, C. L., Oh, E. S., & Smith, K. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.06.044 · Cited by 68
Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis
Reeder, S. B. (2013) · Hepatology · doi:10.1002/hep.26543 · Cited by 53
Doycheva, I., & Loomba, R. S. (2014) · Advances in Therapy · doi:10.1007/s12325-013-0084-6 · Cited by 50
Self-citationMatteucci, E., Giampietro, Giampietro, Masoni, & Bartola, D. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s38346 · Cited by 30
Non-Alcoholic Fatty Liver Disease Adversely Affects the Glycemic Control Afforded by Sitagliptin
Iwasaki, T., Tomeno, W., Yoneda, M., Inamori, M., Shirakawa, J., Imajo, K., Kawashima, K., Terauchi, Y., & Nakajima, A. (2011) · Hepatogastroenterology · doi:10.5754/hge11689 · Cited by 15
Cited by
Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease
Castera, L., Friedrich-Rust, M., & Loomba, R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.036 · Cited by 1,494
Self-citationCusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Tilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002
The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments
Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850
Park, C. C., Nguyen, P., Hernandez, C., Bettencourt, R., Ramirez, K., Fortney, L., Hooker, J., Sy, E., Savides, M. T., Alquiraish, M. H., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.10.026 · Cited by 708
Self-citation
Metadata
- Authors
- Cui, J., Philo, L., Nguyen, P., Hofflich, H., Hernandez, C., Bettencourt, R., Richards, L., Salotti, J., Bhatt, A., Hooker, J., Haufe, W., Hooker, C., Brenner, D. A., Sirlin, C. B., & Loomba, R.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 65
- Issue
- 2
- Pages
- 369-376
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2397785404
- Cited by
- 326
- References
- 48
- FWCI
- 33.53
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.